CGEM Stock Earnings Estimates Increased by HC Wainwright

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Equities researchers at HC Wainwright lifted their Q3 2026 EPS estimates for shares of Cullinan Therapeutics in a research note issued on Friday, October 2nd. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.86) per share for the quarter, up from their prior forecast of ($0.90). HC Wainwright has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.45) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.92) EPS, Q3 2027 earnings at ($0.93) EPS, Q4 2027 earnings at $0.39 EPS and FY2027 earnings at ($1.81) EPS.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Cullinan Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, September 13th. TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Friday, October 2nd. Wedbush raised their target price on Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a research note on Thursday, August 13th. Finally, BTIG Research reaffirmed a “buy” rating and set a $40.00 target price on shares of Cullinan Therapeutics in a report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.71.

Cullinan Therapeutics Price Performance

NASDAQ CGEM opened at $15.63 on Tuesday. Cullinan Therapeutics has a 12 month low of $5.85 and a 12 month high of $23.19. The firm has a market capitalization of $1.01 billion, a PE ratio of -5.04 and a beta of -0.05. The company’s 50 day simple moving average is $19.45 and its 200 day simple moving average is $16.80.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.01).

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new stake in Cullinan Therapeutics during the 2nd quarter worth about $95,289,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Cullinan Therapeutics during the second quarter worth approximately $28,039,000. Dimensional Fund Advisors LP boosted its holdings in shares of Cullinan Therapeutics by 6.7% during the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock worth $12,870,000 after purchasing an additional 57,259 shares during the period. Boone Capital Management LLC purchased a new position in Cullinan Therapeutics during the second quarter valued at approximately $12,828,000. Finally, Boothbay Fund Management LLC acquired a new position in Cullinan Therapeutics in the 4th quarter valued at approximately $12,803,000. 86.31% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Cullinan Therapeutics

In other news, insider Jennifer Michaelson sold 30,000 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $20.26, for a total transaction of $607,800.00. Following the completion of the sale, the insider directly owned 162,844 shares of the company’s stock, valued at $3,299,219.44. This represents a 15.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 8.60% of the company’s stock.

More Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $35 price target, substantially above the recent trading level. The firm raised its Q3 2026 EPS forecast to a loss of $0.86 from $0.90, while also improving its FY2026 estimate to a loss of $3.45 from $3.53. HC Wainwright Has Optimistic Opinion of CGEM Q3 Earnings
• Positive Sentiment: The largest revisions were to longer-term expectations. HC Wainwright raised its FY2027 EPS forecast to a loss of $1.81 from $3.89, improved its Q1 2027 estimate to a loss of $0.44 from $0.95, and now expects Cullinan to produce positive EPS of $0.39 in Q4 2027 versus a prior estimate of a $1.00 loss. These changes suggest analysts see a faster path toward profitability.
• Neutral Sentiment: Despite the upgrades, Cullinan remains unprofitable, with HC Wainwright projecting losses through most of 2026 and 2027. The firm’s FY2026 loss estimate of $3.45 per share is also worse than the broader consensus estimate of a $3.08 loss, limiting the immediate impact of the positive revisions.
• Negative Sentiment: The reports contain no new drug-development, clinical-trial, regulatory, or partnership announcement. As a development-stage biotechnology company, CGEM may need tangible pipeline progress to support the higher valuation implied by the $35 target; the earnings-estimate changes alone have not provided a clear near-term catalyst.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.